A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
Megadott ok: Change in corporate strategy
Key facts
- Where
- Ann Arbor, Aurora, Austin, Baltimore, Bethesda, Billings, Dallas, Fort Wayne, Fort Worth, Greenville, Houston, Jacksonville, Los Angeles, Monterey, Morristown, New York, Norfolk, Orlando, Redondo Beach, Rochester, Rock Hill, San Antonio, San Diego, Santa Barbara, Santa Rosa, Tyler, Vancouver és Worcester, Egyesült ÁllamokSee the 30 sites
- Phase
- 1. fázis
Where in Egyesült Államok
- University of MichiganAnn Arbor, Egyesült ÁllamokNo longer taking part
- Rocky Mountain Cancer CentersAurora, Egyesült ÁllamokNo longer taking part
- Texas Oncology-Austin MidtownAustin, Egyesült ÁllamokNo longer taking part
- University of Maryland Greenebaum Comprehensive Cancer CenterBaltimore, Egyesült ÁllamokNo longer taking part
- The Center for Cancer and Blood Disorders a division of American Oncology Partners of Maryland, PABethesda, Egyesült ÁllamokNo longer taking part
- SCL Health, St. Vincent Frontier Cancer CenterBillings, Egyesült ÁllamokNo longer taking part
- Texas Oncology - Baylor Charles A. Sammons Cancer CenterDallas, Egyesült ÁllamokNo longer taking part
- Fort Wayne Medical Oncology and HematologyFort Wayne, Egyesült ÁllamokNo longer taking part
- Texas Oncology - Fort Worth Cancer CenterFort Worth, Egyesült ÁllamokNo longer taking part
- PRISMA Health/ITORGreenville, Egyesült ÁllamokNo longer taking part
- University of Texas M.D. Anderson Cancer CenterHouston, Egyesült ÁllamokNo longer taking part
- Mayo Clinic- JacksonvilleJacksonville, Egyesült ÁllamokNo longer taking part
- University of California, Los AngelesLos Angeles, Egyesült ÁllamokNo longer taking part
- Pacific Cancer CareMonterey, Egyesült ÁllamokNo longer taking part
- Morristown Medical CenterMorristown, Egyesült ÁllamokNo longer taking part
- Manhattan Hematology OncologyNew York, Egyesült ÁllamokNo longer taking part
- Memorial Sloan-Kettering Cancer CenterNew York, Egyesült ÁllamokNo longer taking part
- Virginia Oncology AssociatesNorfolk, Egyesült ÁllamokNo longer taking part
- Orlando HealthOrlando, Egyesült ÁllamokNo longer taking part
- Torrance Memorial Physician NetworkRedondo Beach, Egyesült ÁllamokNo longer taking part
- Mayo Clinic - RochesterRochester, Egyesült ÁllamokNo longer taking part
- Carolina Blood and Cancer Care AssociatesRock Hill, Egyesült ÁllamokNo longer taking part
- University of Texas Health Science Center at San Antonio, Mays Cancer CenterSan Antonio, Egyesült ÁllamokNo longer taking part
- Sharp Clinical Oncology ResearchSan Diego, Egyesült ÁllamokNo longer taking part
- UCSD Moores Cancer CenterSan Diego, Egyesült ÁllamokNo longer taking part
- Ridley-Tree Cancer CenterSanta Barbara, Egyesült ÁllamokNo longer taking part
- St. Joseph Heritage HeathcareSanta Rosa, Egyesült ÁllamokNo longer taking part
- Texas Oncology - TylerTyler, Egyesült ÁllamokNo longer taking part
- Northwest Cancer Specialists, P.C. - Compass OncologyVancouver, Egyesült ÁllamokNo longer taking part
- Umass Memorial Medical CenterWorcester, Egyesült ÁllamokNo longer taking part
Trial details
- Who runs it
- Aptose Biosciences Inc.
- Trial code
- NCT03893682
- Record updated
- 2025. március 7.
- Original description
This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas who have failed or are intolerant to two or more lines of established therapy or for whom no other treatment options are available.Read full original descriptionShow less
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas who have failed or are intolerant to two or more lines of established therapy or for whom no other treatment options are available.
Inclusion: Age ≥ 18 years; Life expectancy of at least 2 months; ECOG Performance Status ≤ 2; Patients must be able to swallow capsules; Adequate hematologic parameters, unless cytopenias are disease caused; Adequate renal, liver and cardiac function parameters.
Exclusion: Patients with GVHD requiring systemic immunosuppressive therapy; Treatment with other investigational drugs within 14 days prior to first study treatment administration; Uncontrolled leptomeningeal disease, auto-immune hemolytic anemia and uncontrolled and clinical significant disease related metabolic disorder; Clinically significant intravascular coagulation.